Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$20000.0.

  • Heron Therapeutics' Change in Account Payables rose 4736.84% to -$20000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 7803.79%. This contributed to the annual value of $8.5 million for FY2024, which is 5636000.0% up from last year.
  • Per Heron Therapeutics' latest filing, its Change in Account Payables stood at -$20000.0 for Q3 2025, which was up 4736.84% from -$296000.0 recorded in Q2 2025.
  • Heron Therapeutics' Change in Account Payables' 5-year high stood at $9.6 million during Q2 2021, with a 5-year trough of -$7.3 million in Q3 2022.
  • Its 5-year average for Change in Account Payables is $604842.1, with a median of -$20000.0 in 2025.
  • Data for Heron Therapeutics' Change in Account Payables shows a peak YoY increase of 54539.85% (in 2024) and a maximum YoY decrease of 38607.14% (in 2024) over the last 5 years.
  • Over the past 5 years, Heron Therapeutics' Change in Account Payables (Quarter) stood at -$2.1 million in 2021, then tumbled by 59.56% to -$3.3 million in 2022, then surged by 141.54% to $1.4 million in 2023, then increased by 10.22% to $1.5 million in 2024, then tumbled by 101.31% to -$20000.0 in 2025.
  • Its last three reported values are -$20000.0 in Q3 2025, -$296000.0 for Q2 2025, and $624000.0 during Q1 2025.